1385 results about "Blood sugar" patented technology

The invention discloses a chronic disease patient personalized diet and exercise guidance system and method, and relates to the technical field of medical health information, and the system comprises a data sensing module which continuously collects the dynamic physiological data, behavior data and environment variable data of a patient through an intelligent sensing device, the dynamic physiological data comprises a heart rate time sequence, a step number time sequence and a blood glucose concentration time sequence monitored by the wearable device, and the behavior data comprises a medication operation record with a timestamp and a patient's daily symptom self-grading number. According to the personalized diet and exercise guidance system and method for the chronic disease patient, the time synchronization precision of multi-source data is effectively improved, the accuracy of medication compliance monitoring and physiological index correlation analysis is ensured, and by establishing the dynamic correlation model of the environment temperature and the human body metabolic rate, the accuracy of medication compliance monitoring and physiological index correlation analysis is improved. The timeliness and safety of clinical intervention are improved, and powerful support is provided for health management of chronic disease patients.

The invention provides a bifidobacterium animalis subsp. Lactis strain B21247 with a hypoglycemic function and application thereof, and belongs to the technical field of functional microorganisms. The invention relates to a bifidobacterium animalis subsp. Lactis strain B21247 with a hypoglycemic function. The preservation number of the bifidobacterium animalis subsp. Lactis strain B21247 is GDMCC No: 65075. The strain B21247 has a good intestinal colonization function, and has the activity of inhibiting alpha-glucosidase in vitro. Meanwhile, a type 2 diabetes mouse model is used as an experimental model to verify that the strain B21247 achieves the effect of reducing blood sugar by adjusting glycosylated hemoglobin, reducing pancreatic beta cell damage and increasing secretion of intestinal GLP-1, and a new thought is provided for reducing blood sugar or treating diabetes.

The invention discloses a strain of bifidobacterium animalis dipro-60 and a preparation method thereof. The invention further discloses a preparation, and the preparation contains the bifidobacterium animalis dipro-60. The bifidobacterium animalis dipro-60 used in the invention has the ability of producing bile salt hydrolase BSH, the ability of reducing cholesterol, the ability of inhibiting helicobacter pylori and the ability of reducing inflammatory factor TNF-alpha; further animal experiments show that the dipro-60 can improve lipid metabolism related diseases, can significantly reduce weight gain of obese mice induced by high fat, significantly reduce the liver weight of the obese mice, reduce the content of triglyceride and blood sugar in blood, improve intestinal barriers and improve the lipid metabolism related diseases, and the dipro-60 can improve the lipid metabolism related diseases. Liver lipid accumulation caused by obesity or hyperlipidemia is improved, and bone loss caused by obesity or hyperlipidemia is improved.

Compositions and methods for administering ketone bodies to a subject include beta-hydroxybutyrate complexed with or coupled to at least one amino acid. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

The present invention relates to the technical field of microorganisms. Disclosed are lacticaseibacillus paracasei and a postbiotic product prepared therefrom, and a use of both. The present invention provides lacticaseibacillus paracasei (Latin name) YJS05199, which has the preservation number of GDMCC No.63668, and was preserved in Guangdong Microbial Culture Collection Center on 19 July 2023. The present invention further provides a postbiotic prepared by applying the lacticaseibacillus paracasei. The lacticaseibacillus paracasei and the postbiotic prepared therefrom have a bacteriostatic effect, can inhibit the weight gain of a mouse fed with high-fat diets, reduce the adipose tissue weight and the blood glucose concentration, and can remarkably reduce the levels of TG, TC, and LDL-C in serum of the mouse. Thus, the lacticaseibacillus paracasei and the postbiotic prepared therefrom have great application prospects in preparation of products for preventing or treating obesity and related diseases or in preparation of bacteriostatic products.

The invention relates to the technical field of biomedical sensing and health monitoring, and discloses a noninvasive glucose detection system. The system comprises an interstitial fluid extraction device, a photoelectric sensing module and a main control circuit which are integrated on a flexible substrate. The interstitial fluid extraction device drives subcutaneous interstitial fluid to migrate to the hydrogel interface layer under the action of reverse ion electroosmosis; the photoelectric sensing module receives interstitial fluid through a hydrogel interface layer, a working electrode of the photoelectric sensing module comprises a Cu monatomic imprinting recognition layer, and imprinting holes formed by Cu monatomic sites are specifically coordinated with glucose molecules. The master control circuit controls sampling and determines the glucose concentration based on the photocurrent signal. Noninvasive sampling and monatomic imprinting photoelectric detection are fused, sampling-detection integration is achieved, and the device has the advantages of being noninvasive, painless, high in selectivity, high in interference resistance, comfortable to wear and the like and is suitable for continuous monitoring of blood glucose.

The invention discloses a fructus cannabis protein peptide and particle for inhibiting alpha-glucosidase as well as a preparation method and application of the fructus cannabis protein peptide and particle. The fructus cannabis protein peptide for inhibiting alpha-glucosidase comprises at least one of polypeptides of which the amino acid sequences are FY, SPVI, TGLGR and FR. The fructus cannabis protein peptide particles for assisting in reducing blood sugar comprise the following components: fructus cannabis protein peptide powder, a sugar-free auxiliary material, a flavoring agent and an adhesive, the mass ratio of the fructus cannabis protein peptide powder to the sugar-free auxiliary material is (1: 5)-(1: 9), and the addition amount of the flavoring agent is 0.2%-0.8% of the total mass of the fructus cannabis protein peptide powder and the sugar-free auxiliary material. The fructus cannabis protein peptide disclosed by the invention has a very high alpha-glucosidase inhibition rate; according to the particles prepared by screening proper auxiliary materials and proportioning, the stability of the fructus cannabis protein peptide in the storage process and the like can be ensured, and the fructus cannabis protein peptide is high in transfer rate, high in particle forming rate and yield and good in taking taste in the production process and has a good blood sugar reducing effect.

The invention relates to the technical field of phototherapy, in particular to a wearable light blood sugar reducing device and system and an eyeshade. The wearable light hypoglycemic device comprises a wearing unit for a user to wear; the lighting unit is used for projecting red light to human eyes; the driving unit is used for supplying power to the lighting unit; and the control unit is used for adjusting the light-emitting mode of the lighting unit according to a preset regulation and control scheme. According to the preset regulation and control scheme, multiple times of illumination are carried out within preset time, and the interval between every two adjacent times of illumination is preset duration. Red light waves of a specific wave band can be emitted to human eyes according to a preset regulation and control scheme, photosensitive retinal ganglion cells (ipRGCs) can be directly activated, signals are transmitted from optic nerves to series nerve nuclei of hypothalamus and medulla oblongata, finally, the signals act on peripheral brown adipose tissue BAT through sympathetic nerves, the metabolic capacity of blood sugar is affected, and the blood sugar metabolism is improved. And when the embodiment is used for reducing blood sugar, the user only needs to wear the equipment, so that the method is easy to implement.

The dynamic continuous blood glucose monitor comprises a needle assisting device assembly, the needle assisting device assembly comprises a main shell, a push rod base and a push rod, the push rod base and the push rod are movably arranged in the main shell, and an emission spring is arranged between the push rod base and the push rod; the needle assembly comprises a needle clamp and a needle seat which are fixedly assembled, and a needle withdrawing spring is arranged between the needle clamp and the push rod; and the bottom cover is detachably assembled on the main shell. The dynamic continuous blood glucose monitor has the advantages of being simple and reasonable in structural design and easy and convenient to operate, and during use, feeding and withdrawing of the auxiliary needle and smooth implantation of the sensor probe into the human body can be automatically completed only by pressing the main shell; the detachable bottom cover structural design avoids potential safety hazards caused by exposure of structures such as a CGM sensor and an auxiliary needle, and after the device is used once, when the device needs to be used again, a new CGM module is loaded below the main shell again, meanwhile, structures such as the push rod, the push rod seat and the needle clamp are reset, and the bottom cover is screwed back, so that the device is convenient to use. Therefore, the dynamic continuous blood glucose monitor can be reused, and waste is avoided.

The invention relates to a bifidobacterium animalis subsp. Lactis YYSJ001 with a blood sugar reducing effect and application of the bifidobacterium animalis subsp. Lactis YYSJ001. The classification name of the strain is bifidobacterium animalis subsp. Lactis, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.33471. The invention further relates to a preparation method of the bifidobacterium animalis subsp. Lactis YYSJ001. The bacterial strain has good artificial gastric juice resistance, artificial intestinal juice resistance and intestinal tract adhesion ability, has an inhibition effect on numerous pathogenic bacteria such as escherichia coli, staphylococcus aureus, salmonella, klebsiella pneumoniae and quail chicken enterococcus, and can stimulate intestinal cells to generate glucagon-like peptide-1, so that the bacterial strain can be applied to preparation of various pathogenic bacteria. Diseases of diabetic mice can be effectively improved, and the compound can be used for preparing products for preventing and treating diabetes or assisting in reducing blood sugar.

The invention discloses a semaglutide soluble microneedle patch composition. The soluble microneedle patch composition comprises a needle body material and a backing layer material, the material of the needle body can be only composed of a high-concentration semaglutide solution. According to the semaglutide micro-needle patch, the drug loading capacity of semaglutide in the micro-needle patch can be greatly improved, the hypoglycemic effect which is the same as that of subcutaneous injection administration can be achieved under the same administration amount, and a new dosage form choice is provided for the pharmaceutical application of semaglutide, such as hypoglycemic weight reduction and the like.

The invention relates to a preparation method and application of sea buckthorn pomace flavone extract freeze-dried powder, and belongs to the technical field of natural product extraction. The method comprises the following steps: pretreating (drying and powdering) a sea buckthorn pomace raw material, preparing a crude extract, purifying the extract, freeze-drying the extract, and finally obtaining the sea buckthorn pomace flavone extract freeze-dried powder. The by-product sea buckthorn pomace in the sea buckthorn processing process is subjected to resource utilization, the vibration type ultrafine pulverizer is adopted for pulverizing to increase the extraction surface area, the ultrasonic synergistic biological enzymolysis method is adopted for promoting release of active molecules, the efficiency is improved, energy and time are saved, no harmful solvent is used in the extraction process, and the method is environmentally friendly, simple in preparation process and high in operability; the large-scale production is easy to realize. According to the sea buckthorn pomace flavone extract freeze-dried powder prepared by the method, the total flavone extraction amount reaches 17.79-23.05 mg / g of the dry weight of sea buckthorn pomace, the purity can reach 50-65%, and the sea buckthorn pomace flavone extract freeze-dried powder has good oxidation resistance, alpha-glucosidase inhibitory activity and alpha-amylase inhibitory activity and can be used for developing products for reducing blood sugar.

A wearable device for measuring biometric parameters includes a circular or polygonal array of sets of light emitters and light receivers. Light transmitted through body tissue is received and analyzed to measure one or more biometric parameters such as oxygenation level, heart rate, heart rate variability, blood pressure, hydration level, and / or blood glucose level. Each set of light emitters includes light emitters which emit light of different colors. This device can also include one or more compressible opaque light barriers which surround light receivers.

The present disclosure relates to systems, devices and methods for receiving biosensor data acquired by a medical device, e.g., relating to glucose concentration values, and controlling the access and distribution of that data. In some embodiments, systems and methods are disclosed for monitoring glucose levels, displaying data relating to glucose values and metabolic health information, and controlling distribution of glucose data between applications executing on a computer, such as a smart phone. In some embodiments, systems and methods are disclosed for controlling access to medical data such as continuously monitored glucose levels, synchronizing health data relating to glucose levels between multiple applications executing on a computer, and / or encrypting data.

The invention discloses a lactobacillus paracasei SX-M1559 strain and application thereof in preparation of drugs for reducing blood sugar and lipid and resisting inflammation, and belongs to the technical field of microorganisms. The invention discloses a lactobacillus paracasei SX-M1559, and the preservation number of the lactobacillus paracasei SX-M1559 is CCTCC (China Center For Type Culture Collection) NO: M 2025030. According to the lactobacillus paracasei SX-M1559 and the application thereof in preparation of the medicine for reducing blood sugar, blood fat and inflammation, the SX-M1559 is separated from fresh feces of long-life old people, teai county, Zhanjiang city, Guangdong province, the glucose content in a zebra fish hyperglycemia model body and the fat content in a zebra fish hyperlipidemia model body can be remarkably reduced, and the effect of reducing blood sugar, blood fat and inflammation is achieved. The invention provides a theoretical reference and a guidance basis for developing a probiotic preparation for preventing or treating hyperlipidemia, diabetes mellitus and inflammatory bowel disease by utilizing the new strain SX-M1559 of the casei paracasei.

The invention discloses a method for evaluating postprandial blood glucose response of a human body based on continuous blood glucose data and application. The method comprises the following steps: acquiring a continuous blood glucose detection value and meal starting time; matching a first blood glucose recording point after eating according to the dining time, intercepting blood glucose data of 2 hours after meal, and preprocessing the data; constructing four postprandial blood glucose response modes by applying the continuous blood glucose data of FPCA and based on a characteristic function of which the interpretation degree ranks top two obtained by the FPCA; through comparison of postprandial blood glucose response mean value curves of the four blood glucose response modes, the four response modes can evaluate postprandial blood glucose by integrating the blood glucose concentration range and whether the fasting homeostasis can be rapidly recovered or not.

A method may include obtaining blood glucose level readings over a diurnal period for each of a plurality of days and determining an estimated variability of the blood glucose levels over the diurnal period for the plurality of days. The method may also include modifying, based on the estimated variability of the blood glucose level, a target blood glucose level to a modified target blood glucose level, and delivering insulin, using an insulin pump, during the diurnal period based on the modified target blood glucose level.

The invention discloses an ACE (Angiotensin Converting Enzyme) inhibition and DPP-IV (Dipeptidyl Peptidase-IV) inhibition bifunctional peptide as well as a design method and application thereof. The amino acid sequence of the bifunctional peptide fragment is Trp-Ala-Leu-Val-Ala-Pro or Trp-Pro-Leu-Val-Ala-Pro. According to the design method, hydrophobic amino acid replacement is carried out on most N-terminal first amino acid according to the characteristics of the DPP-IV inhibitory peptide, and N-terminal second amino acid is kept as proline Pro or alanine Ala. The difunctional peptide fragment obtained through the DPP-IV inhibitory activity optimization strategy has the effects of assisting in lowering blood pressure and lowering blood sugar at the same time and can be used for preparing functional food or health food with the functions of assisting in lowering blood pressure and lowering blood sugar, and the optimization strategy can be applied to improving the blood sugar lowering effect of the peptide fragment and has good market application prospects.

The invention discloses an intelligent medical remote diagnosis and treatment system based on artificial intelligence, which adopts a convolutional neural network to extract ultrasonic, computed tomography and magnetic resonance imaging characteristics, adopts a long-short term memory network to extract electrocardiogram, blood pressure and blood sugar characteristics, and subsequently fuses the characteristics with an electronic medical record. And finally, the multi-modal local large model is utilized to diagnose the structured data. The specific implementation steps of the system are as follows: S1: data acquisition; s2, data preprocessing; s3, feature extraction; s4, data transmission; s5, performing diagnosis; s6, remote interaction; s7, data analysis; s8, manual verification is carried out; s9, updating the model; the defects that traditional medical image and physiological signal detection is long in consumed time and large in error are overcome, the problem that medical resources are not evenly distributed is effectively solved, and improvement of multi-mechanism cooperation and the overall diagnosis capacity is promoted.

The invention discloses pediococcus acidilactici NDF12 and application thereof, the pediococcus acidilactici NDF12 is preserved in Guangdong Microbial Culture Collection Center on January 8, 2025, is called GDMCC for short, and the preservation number is GDMCC NO: 65732. The invention further discloses a preparation method of the pediococcus acidilactici NDF12. The strain is derived from Chinese local traditional dairy products, phenotype and genotype safety evaluation proves that the strain is safe and non-toxic, has excellent fermentation characteristics and probiotic characteristics, and can be used as a leavening agent for producing yoghourt. The bacterial strain also has gastrointestinal fluid endurance capacity, adhesion capacity, bacteriostatic activity, antioxidant activity, cholesterol lowering activity and blood sugar lowering activity, and has great application prospects in the fields of foods, medicines, feeds and the like.

The present invention provides L-β-galactoglucan, a preparation method therefor, and a use thereof. The polysaccharide is sinistrin, is composed of β-D-glucose and β-D-galactose, and has a molecular weight of not less than 5000 Da. The preparation method for the polysaccharide comprises: inoculating Agrobacterium FN01 in a culture solution for fermentation to obtain a fermentation broth; mixing the fermentation broth with alcohol, and carrying out precipitation and drying to obtain a crude polysaccharide product; and then carrying out purification to obtain a purified polysaccharide product, or carrying out enzymolysis on the fermentation broth by using glucanase, and then carrying out filtration, ultrafiltration concentration, and spray-drying to obtain a purified polysaccharide product. The polysaccharide has the effects of treating and / or preventing liver injury, resisting aging, decreasing blood sugar, repairing tissues and the like, and is a multipurpose polysaccharide.

The invention relates to a plant lactobacillus with hypoglycemic ability, and an application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides a lactobacillus plantarum strain Lp116 with the capability of reducing blood sugar, and the preservation number of the lactobacillus plantarum strain Lp116 is CCTCC (China Center for Type Culture Collection) NO: M 20241784. The invention also provides an application of the strain Lp116 in preparation of hypoglycemic drugs or health-care foods with an auxiliary hypoglycemic function or bacteriostatic agents or non-treatment-destination bacteriostasis, and a product and a method based on the strain Lp116. The strain Lp116 disclosed by the invention has a relatively strong inhibition effect on escherichia coli, staphylococcus aureus, salmonella, streptococcus pharyngobuccal inflammation and streptococcus pseudopneumoniae, and can effectively achieve the effects of reducing blood sugar and regulating intestinal flora.

The invention discloses bullfrog skin-derived peptide LGPQR and a purification method and application thereof.The molecular weight of the bullfrog skin-derived peptide LGPQR is 570.34 Da, and the amino acid sequence of the bullfrog skin-derived peptide LGPQR is shown as SEQ ID NO.1. The bullfrog skin-derived peptide LGPQR is obtained by extracting bullfrog skin enzymatic hydrolysate through an enzymolysis means to construct a polypeptide library, then screening the polypeptide library through computer-aided screening, and then evaluating the screened peptide fragments so as to be optimal. Finally, the purified bullfrog skin source peptide LGPQR is obtained. According to the bullfrog skin-derived peptide LGPQR as well as the purification method and the application thereof, the bullfrog skin-derived peptide LGPQR has relatively good functions of reducing blood sugar and resisting oxidation, has application potential of type II diabetes medicines, and is safe and free of toxic and side effects. The amino acid sequence is short, the operability is high, and the social popularization and application value is good.

The invention relates to the technical field of medical health data intelligent processing, in particular to a gestational diabetes patient family doctor management method and system based on artificial intelligence, and the method comprises the steps: 1, collecting patient data through a dynamic glucometer, a fetal heart monitor and a hospital information system; 2, aligning the multi-source data according to timestamps to construct a time sequence data set; 3, generating a complication risk score containing a ketoacidosis risk and a giant child risk; 4, generating a personalized sugar control scheme based on the risk score and a pre-constructed medical knowledge graph; 5, integrating opinions of multiple parties to generate a final edition scheme; and step 6, updating deep learning model parameters based on feedback data. According to the mode, the treatment efficiency and accuracy are improved, the control scheme can be adjusted in real time, and the health and safety of the patient in the pregnancy period are ensured. In addition, a feedback mechanism can continuously optimize the system, a closed loop is formed, and the management effect is further improved.

The invention discloses a wheat peptide with a hypoglycemic effect as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a bioactive peptide LPQ or LPQF with a hypoglycemic effect, and animal model experiments prove that the bioactive peptide can effectively reduce the blood sugar level and improve related metabolic indexes, and has no obvious side effects. The invention also provides a wheat peptide rich in oligopeptide containing the peptide fragment LPQ, and animal model experiments prove that the wheat peptide has a remarkable effect in the aspect of reducing blood sugar. The invention provides a safe and effective alternative scheme for development of diabetes treatment drugs, and has good market prospects and application potential.

The invention relates to ackermania muciniphila Akk21 with hypoglycemic capacity and application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides an ackermania muciniphila strain Akk21 with a blood sugar reducing capability. The preservation number of the ackermania muciniphila strain Akk21 is CCTCC (China Center for Type Culture Collection) NO: M 20242779. The invention also provides hypoglycemic drugs, functional food for promoting lead excretion, health care products and a method for preventing and treating lead / arsenic pollution based on the strain Akk21. The Ackermania muciniphila Akk21 has excellent lead and arsenic tolerance and hypoglycemic capacity, can effectively reduce the blood lipid level of mice with type II diabetes, has a remarkable reduction effect on inflammation of the whole body of the mice, and can remarkably reduce the number of harmful flora in the intestinal tract by increasing the abundance of effective flora in the intestinal tract, so that the content of the harmful flora in the intestinal tract is reduced, and the content of the harmful flora in the intestinal tract is reduced. The species diversity and abundance of intestinal flora are improved.

The invention provides application of combined cholic acid TrpCA and producing bacteria thereof in treating and preventing metabolic diseases. The present invention relates to the use of tryptophan-binding cholic acid or a producing bacterium thereof in the preparation of a composition for preventing and / or treating a metabolic disease or for promoting the production of GLP-1 and / or insulin. The inventor finds for the first time that tryptophan-bound cholic acid can remarkably promote secretion of GLP-1 on an in-vivo animal model and an in-vitro cell model, the effects of reducing weight, reducing blood sugar and relieving the symptoms of the non-alcoholic fatty liver disease are achieved, and the same metabolism improvement effect can also be achieved through planting of probiotics capable of generating cholic acid TrpCA.

An α-amylase inhibitory peptide. The peptide comprises amino acid sequences of eight adjacent amino acids X1, X2, X3, X4, X5, X6, X7, and X8, wherein each amino acid of the peptide is independently selected from a D-amino acid or an L-amino acid, and at least one of X2, X4, and X6 is W. The peptide has α-amylase inhibitory activity, has the effects of losing weight and lowering blood sugar, and can be used for preparing α-amylase inhibitors, weight-losing drugs, hypoglycemic drugs, or foods, health-care products or drugs for preventing or treating obesity-related diseases.

In some examples, a system includes a glucose sensor configured to generate a signal indicative of a blood glucose level of a patient, a medical device configured to deliver insulin to the patient, a peritoneal dialysis (PD) device, and control circuitry. The control circuitry is configured to control the PD device to deliver PD therapy to a patient during a PD cycle, determine a blood glucose level of the patient during the PD cycle based on a signal from the glucose sensor, determine that the blood glucose level is greater than or equal to a predetermined blood glucose level threshold, and control the medical device to deliver insulin to the patient in response to determining the blood glucose level is greater than or equal to the predetermined blood glucose level threshold.

The invention belongs to the technical field of bioengineering, and particularly relates to leuconostoc mesenteroides subsp. Mesenteroides FTCM002 and application thereof in preparation of dendrobium officinale leavening with the effects of reducing blood sugar, nourishing the stomach and resisting inflammation. Dendrobium officinale is subjected to enzymolysis and inoculated with the strain for fermentation, and the obtained fermented dendrobium officinale has the effect of inhibiting alpha-glucosidase; the gastric mucosal injury can be relieved, the expression of VEGF, IL-6, IL-8 and TNF-alpha in the gastric mucosal injury is reduced, and the effect of nourishing the stomach is achieved; the cell phagocytic rate can be increased, the NO concentration and the content of immune factors IL-6 and TNF-alpha can be increased, and the effect of enhancing the immunity is achieved; the expression quantity of IL-6, IL-1beta and TNF-alpha in inflammatory cells can be reduced, and the anti-inflammatory effect is achieved.